Palliative Chemotherapy (2nd line) with Imatinib (Glivec™) in Patients with Bile Duct Cancer

| Recruitment status | [X] Prospectively registered |
|----------------------|-------------------------------|
| Stopped | ☐ Protocol |
| Overall study status | Statistical analysis plan |
| Stopped | Results |
| Condition category | Individual participant data |
| | Record updated in last year |
| | Stopped Overall study status |

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Dr Marcus Wiedmann

Contact details

Philipp-Rosenthalstr. 27 Leipzig Germany 04103 +49 (0)34 1971 2230 wiedm@medizin.uni-leipzig.de

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers
CSTI571BDE55

Study information

Scientific Title

Acronym

GlivecGG

Study objectives

The aim is to assess the pharmacokinetics and efficacy of imatinib in patients with bile duct cancer and to test Positron Emission Tomography (PET) as a diagnostic tool.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Approved by the Local Ethics Committee of Leipzig University on 28 November 2005.

Study design

Non-randomised open label multicentre study

Primary study design

Interventional

Secondary study design

Non randomised controlled trial

Study setting(s)

Hospital

Study type(s)

Treatment

Participant information sheet

Not available in web format, please use the contact details below to request a patient information sheet

Health condition(s) or problem(s) studied

Non-resectable bile duct cancer

Interventions

- 1. Continuous second line chemotherapy with imatinib assessment of response by tumor marker and imaging during follow-up
- 2. Generation of pharmacokinetic data during the first two days of drug administration and during the following weeks
- 3. Assessment of the efficacy of PET for evaluation of early treatment response

Added 01/09/09: trial was stopped prematurely due to a lack of a sufficient number of patients (9 in three and a half years).

Intervention Type

Drug

Phase

Not Specified

Drug/device/biological/vaccine name(s)

Imitanib (Glivec)

Primary outcome measure

- 1. Response rate
- 2. Median duration of objective remission

Secondary outcome measures

- 1. Time to progression
- 2. Median survival
- 3. Tumor response after one week or three months by 18-fluorodeoxyglucose-Positron Emission Tomography (18 FDG-PET)
- 4. Toxicity
- 5. Pharmacokinetics

Overall study start date

01/03/2006

Completion date

28/02/2010

Reason abandoned (if study stopped)

Participant recruitment issue

Eligibility

Key inclusion criteria

- 1. Two-dimensional detectable tumors or metastasis
- 2. Aged between 18 and 75 years
- 3. General condition World Health Organisation (WHO) <2
- 4. Live expectancy of at least three months
- 5. Informed consent
- 6. Bilirubin not to be elevated more than upper normal value (1.5 times in the presence of liver metastasis) and alanine aminotransferase (ALT) or aspartate aminotransferase (AST) more than
- 1.5 times (2.5 times in the presence of liver metastasis) of the upper normal value
- 7. Creatinine <133 μ mol/l (<1.5 mg/l), creatinine clearance >60 ml/min

Participant type(s)

Patient

Age group

Adult

Lower age limit

Sex

Both

Target number of participants

40 - recruitment closed on 31/08/09 (9 recruited).

Key exclusion criteria

- 1. Pregnant and lactating women, fertile men and women without adequate contraception
- 2. Patients that have not received primary chemotherapy
- 3. Pre-operated tumor recurrence
- 4. Tumor extent >50% of the liver or >25% of the lung, abdominal mass >10 cm, Central Nervous System (CNS) metastasis
- 5. Ileus
- 6. Non-measurable tumor
- 7. Known intolerance to imatinib and its preservatives
- 8. Second malignancy
- 9. Second unstable disease
- 10. Co-medication with non-approved drugs
- 11. Any other anti-cancer treatment
- 12. Co-medication with paracetamol

Date of first enrolment

01/03/2006

Date of final enrolment

28/02/2010

Locations

Countries of recruitment

Germany

Study participating centre Philipp-Rosenthalstr. 27 Leipzig

Germany 04103

Sponsor information

Organisation

University of Leipzig (Germany)

Sponsor details

Ritterstr. 26 Leipzig Germany 04109 wiedm@medizin.uni-leipzig.de

Sponsor type

University/education

ROR

https://ror.org/03s7gtk40

Funder(s)

Funder type

Industry

Funder Name

Novartis Pharma GmbH (Germany)

Funder Name

Business Unit Oncology (Geschäftseinheit Onkologie) (Germany)

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration